More insurance plans than ever are offering Taltz as the Preferred IL-17A antagonist across Commercial and Part D.
Learn moreDermatology Efficacy
Week 12 results
Efficacy you can see
Week 60 results
FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Reassure your patients that consistent results can be maintained with Taltz at week 601,6
In the maintenance period of UNCOVER-1 & -2, 75% of the patients receiving Taltz every 4 weeks who achieved sPGA 0,1 at week 12, maintained that response at week 60 (n=181*) compared with 7% of patients receiving placebo (n=203*) (NRI).
Patients who achieved clear or almost clear skin (sPGA 0,1) after initial treatment with Taltz 80 mg every 2 weeks were re-randomized at week 12 to receive either Taltz 80 mg every 4 weeks (n=181*) or placebo (n=203*).
*Evaluable patients at week 60.
NRI=nonresponder imputation.
SELECT IMPORTANT SAFETY INFORMATION: IMMUNIZATIONS
Prior to initiating Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.
Week 264 results
FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Rapid response at week 12 and durable efficacy through 5 years7-10
Induction period and open-label extension
In an observed analysis of UNCOVER-3 (Taltz N=385), at week 12, 92% of patients receiving Taltz achieved PASI 75, 72% of patients achieved PASI 90, and 40% of patients achieved PASI 100. Additionally, at weeks 60, 108, 156, 204, and 264, 96%, 94%, 97%, 98%, and 97% of patients receiving Taltz, respectively, achieved PASI 75; 84%, 81%, 87%, 88%, and 90% of patients, respectively, achieved PASI 90; and 64%, 58%, 65%, 67%, and 66% of patients, respectively, achieved PASI 100.
In an mNRI analysis of UNCOVER-3, at week 12, 90% of patients receiving Taltz achieved PASI 75, 70% of patients achieved PASI 90, and 39% of patients achieved PASI 100. Additionally, at weeks 60, 108, 156, 204, and 264, 89%, 82%, 84%, 83%, and 79% of patients receiving Taltz, respectively, achieved PASI 75; 78%, 71%, 69%, 66%, and 67% of patients, respectively, achieved PASI 90; and 59%, 50%, 49%, 48%, and 46% of patients, respectively, achieved PASI 100.
These were post hoc analyses of ITT population through week 264.
A subset of patients from UNCOVER-3 who received a 160 mg starting dose of Taltz at week 0, followed by 80 mg every 2 weeks through week 12, followed by 80 mg every 4 weeks, is shown.
The open-label phase of the study beginning after week 12 has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).
mNRI analysis imputes missing data due to study drug (eg, inadequate response, adverse event, lack of efficacy) as nonresponse; whereas missing data due to other reasons (eg, missed visits, lost to follow-up) is included as a predicted value based on statistical modeling of observed data.
mNRI=modified nonresponder imputation; ITT=intent-to-treat.
SELECT IMPORTANT SAFETY INFORMATION: ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis, and conjunctivitis, influenza, and urticaria in pediatric psoriasis.
Rapid clearance by week 12 that was sustained through week 26410-13
In an observed analysis of UNCOVER-3 (Taltz n=385; placebo n=193), at weeks 2, 4, 8, and 12 (the induction period), patients receiving Taltz achieved mean percentage improvement in PASI from baseline of 56%, 74%, 86%, and 92%, respectively, vs 11%, 13%, 15%, and 14% for placebo, respectively. Additionally, at weeks 36, 48, 60, 108, 156, 204, and 264 (the open-label extension period), patients receiving Taltz achieved 95%, 95%, 96%, 95%, 96%, 97% and 97% of mean percentage improvement in PASI from baseline, respectively.
In an observed analysis of UNCOVER-3 (Taltz n=385; placebo n=193), at baseline and weeks 2, 4, 8, and 12, patients receiving Taltz achieved mean PASI score of 20.7, 9.2, 5.5, 2.8, and 1.6, respectively, vs 21.1, 18.9, 18.4, 17.8 and 17.9 for placebo, respectively. Additionally, at weeks 36, 48, 60, 108, 156, 204, and 264, patients receiving Taltz achieved mean PASI score of 1.0, 1.0, 0.8, 1.1, 0.7, 0.6, and 0.7, respectively.
Post hoc observed analyses of ITT population through week 264.
In UNCOVER-1, patients receiving Taltz achieved a mean PASI of 1.9 (an 88% improvement from the mean baseline score of 20.1) at week 12. Patients receiving placebo achieved a mean PASI of 18.9 (a 3% improvement from the mean baseline score of 20.3) at week 12.12,13
In UNCOVER-2, patients receiving Taltz achieved a mean PASI of 1.7 (a 91% improvement from the mean baseline score of 19.4) at week 12. Patients receiving placebo achieved a mean PASI of 19.1 (a 7% improvement from the mean baseline score of 20.6) at week 12.12
A subset of patients with moderate to severe plaque psoriasis from UNCOVER-3 who received a 160 mg starting dose of Taltz at week 0, followed by 80 mg every 2 weeks through week 12, followed by 80 mg every 4 weeks, is shown. Patients and site personnel were blinded to study treatment until all patients completed week 12 or discontinued.
The open-label extension phase of the study has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).
SELECT IMPORTANT SAFETY INFORMATION: CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Trust Taltz to deliver7,8,14-18
- Rapid clearance data (PASI 75) as early as week 2
- Long-term complete clearance data sustained through 5 years
- Data in challenging body areas , including scalp, nail, genital, and palmoplantar
- Demonstrated long-term safety data through 5 years and across 15 clinical trials
- Efficacy data in psoriatic arthritis

Hypothetical patient.
UNCOVER-1, -2, and -3 , SPIRIT-P1 and -P2 , and IXORA-R trial designs.
*Based on new prescriptions and total prescriptions, inclusive of inhibitors targeting IL-17A/F.
PASI=Psoriasis Area Severity Index; PASI 75=75% improvement from baseline in PASI criteria; IL-17A/F=interleukin-17A/F.
SELECT IMPORTANT SAFETY INFORMATION: INFECTIONS
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.
References: 1. Taltz [package insert]. Indianapolis, IN: Lilly USA, LLC. 2. Data on file. Lilly USA, LLC. TAL20160222D. 3. Data on file. Lilly USA, LLC. TAL20160222A. 4. Data on file. Lilly USA, LLC. TAL20160222E. 5. Data on file. Lilly USA, LLC. TAL20160222B. 6. Data on file. Lilly USA, LLC. DOF-IX-US-0274. 7. Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85:360-368. 8. Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. Supplementary material. J Am Acad Dermatol. 2021;85:360-368. 9. Data on file. Lilly USA, LLC. DOF-IX-US-0197. 10. Data on file. Lilly USA, LLC. DOF-IX-US-0209. 11. Data on file. Lilly USA, LLC. DOF-IX-US-0232. 12. Data on file. Lilly USA, LLC. DOF-IX-US-0051. 13. Data on file. Lilly USA, LLC. DOF-IX-US-0272. 14. Blauvelt A, Papp K, Gottlieb A, et al; IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182:1348-1358. 15. Guenther L, Potts Bleakman A, Weisman J, et al. Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial. Acta Derm Venereol. 2020;100:adv00006. 16. Mease PJ, van der Heijde D, Ritchlin CT, et al; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79-87. 17. Nash P, Kirkham B, Okada M, et al; SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389:2317-2327. 18. Data on file. Lilly USA, LLC. DOF-IX-US-0256. 19. Data on file. Lilly USA, LLC. DOF-IX-US-0292.
INDICATIONS
Taltz is indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. Taltz is also indicated for adult patients with active psoriatic arthritis (PsA), adult patients with active ankylosing spondylitis (AS), and adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.
Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.
Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.
Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.
ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.
Please click to access the Prescribing Information and Medication Guide . Please see Instructions for Use included with the device.
IX HCP ISI 07MAY2020